Skip to main content
Fig. 4 | Radiation Oncology

Fig. 4

From: Investigating the potential of proton therapy for hypoxia-targeted dose escalation in non-small cell lung cancer

Fig. 4

Distribution of NTCP for homogeneous dose prescription photon (blue), proton (black) and dose escalated proton plans (red) of the whole cohort. Significant (Wilcoxon Signed Rank Test) NTCP reductions are observed for the dose-escalated proton plans in lungs, heart and esophagus (excluding the Wang et al. [28] model) compared to the photon plans. Dose escalated did not result in significant increases in NTCP compared to the homogeneous dose prescription proton plans

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us